GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (LTS:0HNC) » Definitions » Gross-Profit-to-Asset %

Biomarin Pharmaceutical (LTS:0HNC) Gross-Profit-to-Asset % : 33.59% (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Biomarin Pharmaceutical Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Biomarin Pharmaceutical's annualized Gross Profit for the quarter that ended in Mar. 2025 was $2,374 Mil. Biomarin Pharmaceutical's average Total Assets over the quarter that ended in Mar. 2025 was $7,068 Mil. Therefore, Biomarin Pharmaceutical's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 33.59%.


Biomarin Pharmaceutical Gross-Profit-to-Asset % Historical Data

The historical data trend for Biomarin Pharmaceutical's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Gross-Profit-to-Asset % Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.36 23.21 25.74 28.56 32.88

Biomarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.55 33.38 32.03 35.33 33.59

Competitive Comparison of Biomarin Pharmaceutical's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Biomarin Pharmaceutical's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Gross-Profit-to-Asset % falls into.


;
;

Biomarin Pharmaceutical Gross-Profit-to-Asset % Calculation

Biomarin Pharmaceutical's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=2273.68/( (6841.603+6988.94)/ 2 )
=2273.68/6915.2715
=32.88 %

Biomarin Pharmaceutical's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=2374.348/( (6988.94+7147.007)/ 2 )
=2374.348/7067.9735
=33.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Biomarin Pharmaceutical Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines